HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

Nature Medicine

Volumn 1, Issue 4, 1995, Pages 321-329

  Abimiku, Alash'le G ^a,f   Franchini, Genoveffa ^a,f   Tartaglia, James ^b   Aldrich, Kristine ^a,f   Myagkikh, Maria ^a,f   Markham, Phillip D ^c   Chong, Pele ^d   Klein, Michel ^d   Kieny, Marie Paule ^e   Paoletti, Enzo ^b   Gallo, Robert C ^a,f   Robert Guroff, Marjorie ^a,f  

^a Laboratory of Tumor Cell Biology ^*  (United States)

^b Virogenetics Corporation   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d Connaught Laboratories ^*  (Canada)

^e TRANSGENE S A   (France)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMAL; AVIPOXVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HIV-2; IMMUNIZATION, SECONDARY; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PILOT PROJECTS; PROTEIN PRECURSORS; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0028942631     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0495-321     Document Type: Article

References (50)

1. Myers, G. et al. Human Retroviruses and AIDS 1994.(Los Alamos National Laboratory, Los Alamos, New Mexico, 1994).
2. Guyader, M. et al. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326, 662-669 (1987).
3. Clavel, F. et al. Isolation of a new human retrovirus from west African patients with AIDS. Science 233, 343-346 (1986).
4. Romieu, I., Marlink, R., Kanki, P., M'Boup, S. & Essex, M. HIV-2 link to AIDS in West Africa. J. Acquir. Immune Defìc. Syndr. 3, 220-230 (1990).
5. Donnelly, C., Leisenring, W., Kanki, P., Awerbuch, T., Sandberg, S. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal. Bull. Math. Biol. 55, 731-743 (1993).
6. Kanki, P.J. et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343, 943-946 (1994).
7. Marlink, R. et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265, 1587-1590 (1994).
8. Tartaglia, J. et al. NYVAC: A highly attenuated strain of vaccinia virus. Virology 188, 217-232 (1992).
9. Tartaglia, J. et al. Novel poxvirus strains as research tools and vaccine vectors. In AIDS Research Reviews, Vol. 3 (eds. Koff, W.C., Wong-Staal, F. & Kennedy, R.C.). 361-378 (Marcel Dekker, New York, 1993).
10. Cadoz, M. et al. Immunisation with canarypox virus expressing rabies glycoprotein, Lancet 339, 1429-1432 (1992).
11. Tartaglia, J., Jarrett, O., Neil, J.C., Desmettre, P., Paoletti, E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J. Virol. 67, 2370-2375 (1993).
12. Agy, M.B. et al. Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science 257, 103-106 (1992).
13. Dormant, D. et al. HIV-2 in rhesus monkeys: Serological, virological and clinical results. Intervirology 30(suppl 1), 59-65 (1989).
14. Nicol, I. et al. Persistent HIV-2 infection of rhesus macaque, baboon, and mangabeys. Intervirology 30, 258-267 (1989).
15. Putkonen, P. et al. Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. J. Acquir. Immune Deftc. Syndr. 2, 366-373 (1989).
16. Franchini, G. et al. Persistent infection of Rhesus macaques with a molecular clone of human immunodeficiency virus type 2: Evidence of minimal genetic drift and low pathogenetic effects. J. Virol. 64, 4462-4467 (1990).
17. Franchini, G. et al. Highly attenuated HTLV-Ienv poxvirus vaccines induce protection against a cell-associated HTLV-I challenge in rabbits, AIDS Res. Hum. Retroviruses 11, 307-313 (1995).
18. Palker, T.J. et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. natn. Acad. Sci. U.S.A. 85, 1932-1936 (1988).
19. Rusche, J.R. et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-aminó acid sequence of the viral envelope, gpl20, Proc. natn. Acad. Sci. U.S.A. 85, 3198-3202 (1988).
20. Goudsmit, J. et al. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. natn. Acad. Sci. U.SA. 85, 4478-4482 (1988).
21. Javaherian, K. et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. natn. Acad. Sci. U.S.A. 86, 6768-6772 (1989).
22. Berzofsky, J.A. Approaches and issues in the development of vaccines against HIV. J. Acquir. Immune Defìc. Syndr. 4, 451-459 (1991).
23. Carlson, J.R. et al. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6, 1239-1246 (1990).
24. Sutjipto, S. et al. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol. 64, 2290-2297 (1990).
25. Weiss, R.A. et al. HIV-2 antisera cross-neutralize HIV-1. AIDS 2, 95-100 (1988).
26. Bottiger, B. et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135). AIDS Res. Hum. Retroviruses 5, 525-533 (1990).
27. Robert-Guroff, M. et al. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J. Virol. 66, 3602-3608 (1992).
28. Bottiger, B. et al. Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: Correlation between cross-neutralization and reactivity against the main neutralizing site. J. Virol. 64, 3492-3499 (1990).
29. Nixon, D.F. et al. An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS 4, 841-845 (1990).
30. Rowland-Jones, S. et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med. 1, 59-64 (1995).
31. Abimiku, A.G. et al. Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2. AIDS Res. Hum. Retroviruses 11, 383-393, (1995).
32. Norley, S.G. et al. Demonstration of cross-reactive antibodies able to elicit lysis of both HIV-1-and HIV-2-infected cells. J. Immunol. 145, 1700-1705 (1990).
33. Piccini, A., Perkus, M.E., Paoletti, E. Vaccinia virus as an expression vector. In Methods in Enzymology, Vol. 153 (eds. Wu, R., Grossman, L.) 545-563 (Academic Press, New York, 1987).
34. Perkus, M.E., Limbach, K., Paoletti, E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J. Virol. 63, 3829-3836 (1989).
35. Vos, J.C., Stunnenberg, H.G. Derepression of a novel class of vaccinia virus genes upon DNA replication. EMBO J. 7, 3487-3492 (1988).
36. Ratner, L. et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284 (1985).
37. Cox, W.I., Tartaglia, J., Paoletti, E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195, 845-850 (1993).
38. Guo, H.G. et al. Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage. Virology 174, 217-224 (1990).
39. Wang, C.Y. et al. Long-term high-titre neutralizing activity induced by oc-tameric synthetic HIV-1 antigen. Science 254, 285-288 (1991).
40. Chong, P., Sia, C., Sydor, M., Klein, M. Identification of a potent synthetic HIV1 immunogen compromising gag-P24 tandem T-and B-cell epitopes. FEBSLett. 264, 231-234 (1990).
41. Kalyanaraman, V.S. et al. Characterization of the secreted, native gpl20 and gpl60 of the human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 6, 371-380 (1990).
42. Nair, B.C. et al. Enzyme immunoassay using native envelope glycoprotein (gpl60) for detection of human immunodeficiency virus type 1 antibodies. J. clin. Micro. 32, 1449-1456 (1994).
43. Robert-Guroff, M. Neutralizing antibodies. In Techniques in HIV Research, (eds. Aldovini, A., Walker, B.D.) 179-185 (Stockton Press, New York, 1990).
44. Salter, R.D., Howell, D.N., Cresswell, P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21, 235-246 (1985).
45. Takahashi, H. et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gpl60 recognized by class I major histocompatibility complex complex molecule-restricted murine cytotoxic T lymphocytes. Proc. natn. Acad. Sci. U.S.A. 85, 3105-3109 (1988).
46. Cease, K.B. et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gpl20 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide Proc. natn. Acad. Sci. U.S.A. 84, 4249-4253 (1987).[Published erratum appears in Proc. natn. Acad. Sci. U.S.A. 1988 Nov; 85 (21):8226].
47. Hale, P.M. et al. T cell multideterminant regions in the human immunodeficiency virus envelope: Toward overcoming the problem of major histocompatibility complex restriction. Int. Immunol. 1, 409-415 (1989).
48. Achour, A. et al. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) pl7, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc. natn. Acad. Sci. U.S.A. 87, 7045-7049 (1990)
49. Nishanian, P.G., Ojo-Amaize, E., Uittenbogaart, C.H., Giorgi, J.V. A simple and rapid method for preparation of HIV-expressing targets for functional assays. J. Immunol. Methods 107, 261-271 (1988).
50. Townsend, A.R.M. et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959-968 (1986).